Lv5
978 积分 2024-09-27 加入
Tirzepatide—New Evidence for the Treatment of Obesity From China
2小时前
待确认
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
1个月前
已完结
Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
1个月前
已完结
[Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)]
2个月前
已完结
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2个月前
已完结
A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
5个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
6个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
6个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
6个月前
已完结
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
